

JosÃ© M GonzÃ¡lez-Navajas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3157562/publications.pdf>

Version: 2024-02-01

54
papers

4,054
citations

257101

24
h-index

161609

54
g-index

56
all docs

56
docs citations

56
times ranked

8414
citing authors

#	ARTICLE	IF	CITATIONS
1	Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2230.	1.8	10
2	The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 625783.	2.2	34
3	The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 625667.	2.2	32
4	Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers. <i>Hepatology International</i> , 2020, 14, 858-868.	1.9	3
5	The Emerging Relevance of AIM2 in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6535.	1.8	21
6	Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis. <i>Cells</i> , 2020, 9, 1227.	1.8	13
7	Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses. <i>ELife</i> , 2020, 9, .	2.8	24
8	Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of <i>B. pseudocatenuatum</i> CECT 7765. <i>European Journal of Nutrition</i> , 2019, 58, 1647-1658.	1.8	13
9	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. <i>FASEB Journal</i> , 2019, 33, 11595-11605.	0.2	68
10	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	1.6	766
11	Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation. <i>Scientific Reports</i> , 2019, 9, 835.	1.6	16
12	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1357-1366.	0.9	5
13	Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. <i>Liver International</i> , 2018, 38, 295-302.	1.9	12
14	Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Short-Chain Fatty Acids in Experimental Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 1610-1623.	2.0	15
15	Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial <sc>DNA</sc> in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 2219-2227.	1.9	17
16	AIM2 deficiency reduces the development of hepatocellular carcinoma in mice. <i>International Journal of Cancer</i> , 2018, 143, 2997-3007.	2.3	30
17	Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. <i>Scientific Reports</i> , 2017, 7, 46425.	1.6	24
18	The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis. <i>Pancreatology</i> , 2017, 17, 364-371.	0.5	18

#	ARTICLE	IF	CITATIONS
19	IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA. <i>Journal of Molecular Medicine</i> , 2017, 95, 1227-1236.	1.7	9
20	Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. <i>Liver International</i> , 2017, 37, 212-223.	1.9	28
21	Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis. <i>Liver International</i> , 2016, 36, 1811-1820.	1.9	12
22	The digestive tract as the origin of systemic inflammation. <i>Critical Care</i> , 2016, 20, 279.	2.5	92
23	<i>Bifidobacterium pseudocatenulatum</i> CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. <i>European Journal of Nutrition</i> , 2016, 55, 197-206.	1.8	23
24	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 529-540.	0.2	34
25	<i>Bifidobacterium pseudocatenulatum</i> CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, 135-145.	1.8	31
26	Inflammasome activation in decompensated liver cirrhosis. <i>World Journal of Hepatology</i> , 2016, 8, 207.	0.8	11
27	Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice. <i>Mucosal Immunology</i> , 2015, 8, 505-515.	2.7	42
28	Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 147-154.	1.4	25
29	Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2015, 50, 758-768.	2.3	10
30	Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 64-71.	1.8	41
31	Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. <i>World Journal of Gastroenterology</i> , 2015, 21, 11493.	1.4	16
32	Protective effect of <i>Bifidobacterium pseudocatenulatum</i> CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. <i>Liver International</i> , 2014, 34, 850-858.	1.9	41
33	The immediate protective response to microbial challenge. <i>European Journal of Immunology</i> , 2014, 44, 2536-2549.	1.6	8
34	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. <i>Gut</i> , 2014, 63, 272-280.	6.1	62
35	The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4+ T cells. <i>Nature Immunology</i> , 2014, 15, 1055-1063.	7.0	193
36	Role of interleukin 10 in norfloxacin prevention of luminal free endotoxin translocation in mice with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 799-808.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Modulation of Inflammatory Response in a Cirrhotic Rat Model with Induced Bacterial Peritonitis. PLoS ONE, 2013, 8, e59692.	1.1	3
38	Autophagy Suppresses Interleukin-1 β (IL-1 β) Signaling by Activation of p62 Degradation via Lysosomal and Proteasomal Pathways. Journal of Biological Chemistry, 2012, 287, 4033-4040.	1.6	82
39	Type I Interferons Maintain Foxp3 Expression and T-Regulatory Cell Functions Under Inflammatory Conditions in Mice. Gastroenterology, 2012, 143, 145-154.	0.6	72
40	Beta-Adrenergic Receptor 1 Selective Antagonism Inhibits Norepinephrine-Mediated TNF-Alpha Downregulation in Experimental Liver Cirrhosis. PLoS ONE, 2012, 7, e43371.	1.1	12
41	Immunomodulatory functions of type I interferons. Nature Reviews Immunology, 2012, 12, 125-135.	10.6	843
42	ERK activation drives intestinal tumorigenesis in Apcmin/+ mice. Nature Medicine, 2010, 16, 665-670.	15.2	182
43	Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. Journal of Experimental Medicine, 2010, 207, 2799-2807.	4.2	64
44	Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10638-10643.	3.3	146
45	TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. Journal of Clinical Investigation, 2010, 120, 570-581.	3.9	143
46	THE PROTECTIVE EFFECTS OF TYPE-1 INTERFERON IN MODELS OF INTESTINAL INFLAMMATION. Advances in Experimental Medicine and Biology, 2009, 633, 1-6.	0.8	3
47	Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology, 2008, 47, 978-985.	3.6	152
48	Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis. Hepatology, 2008, 48, 1924-1931.	3.6	141
49	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. Journal of Hepatology, 2008, 48, 61-67.	1.8	61
50	Bacterial translocation is downregulated by anti-TNF- α monoclonal antibody administration in rats with cirrhosis and ascites. Journal of Hepatology, 2007, 46, 797-803.	1.8	48
51	Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clinical and Experimental Immunology, 2007, 150, 230-237.	1.1	32
52	Bacterial DNA Induces the Complement System Activation in Serum and Ascitic Fluid from Patients with Advanced Cirrhosis. Journal of Clinical Immunology, 2007, 27, 438-444.	2.0	36
53	The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology, 2006, 44, 633-639.	3.6	88
54	A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology, 2004, 39, 484-491.	3.6	132